Safety and efficacy pharmacogenomics in pediatric psychopharmacology

Primary Psychiatry

Volumn 17, Issue 5, 2010, Pages 53-58

  Wall, Christopher A ^a   Oldenkamp, Catherine ^a   Swintak, Cosima ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; ARTICLE; CHILD PSYCHIATRY; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE QUALITY; HUMAN; HYPERPROLACTINEMIA; METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; PARKINSONISM; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 77951720715     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health. 2008;29:115-129.
2. McVoy M, Findling R. Child and Adolescent Psychopharmacology Update. Psychiatr Clin North Am. 2009;32(1):111-133.
3. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug events in the outpatient setting: An 11-year national analysis. Pediatrics. 2009;124(4):e744-e750.
4. Thomas CR, Holzer CE. The continuing shortage of child and adolescent psychiatrists. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1023-1031.
5. Mrazek DA. Pharmacogenomics of methylphenidate response: making progress. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1140-1142.
6. Husain A, Loehle JA, Hein DW. Clinical pharmacogenetics in pediatric patients. Pharmacogenomics. 2007;8(10):1403-1411.
7. Pickar D. Pharmacogenomics of psychiatric drug treatment. Psychiatr Clin North Am. 2003;26(2):303-321.
8. Mrazek D. Psychiatric Pharmacogenomics. New York, NY: Oxford University Press; 2010.
9. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9(8):738-784.
10. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283-289.
11. Wall CA, Wells L, Mohan A, Odegarden S, Drews M, Mrazek DA. Pharmacogenomics and its emerging role in individualized pediatric psychopharmacology. Poster presented at the 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Chicago, IL; October 28-November 2, 2008.
12. Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat Rev Genet. 2004;5(9):645-656.
13. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. November 11, 2009. [Epub ahead of print].
14. Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology. 2009;59(4):222-226.
15. Subuh Surja AA, Reynolds KK, Linder MW, El-Mallakh RS. Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case-control study. Per Med. 2008;5(4):361-365.
16. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol. 2000;56(9-10):679-683.
17. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet. 2003;13(3):163-168.
18. Kobylecki CJ, Hansen T, Timm S, et al. The impact of CYP2D6 and CYP2C19 Polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. Ther Drug Monit. 2008;30(3):265-270.
19. Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry. 2002;35(3):116-118.
20. Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclopenthixol decanoate: Associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology. 2002;162(1):67-73.
21. Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet. 2000;10(1):9-11.
22. Koski A, Sistonen J, Ojanperä I, Gergov M, Vuori E, Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int. 2006;158(2-3):177-183.
23. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361(8):827-828.
24. Stamer UM, Stüber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg. 2008;107(3):926-929.
25. He YJ, Brockmöller J, Schmidt H, Roots I, Kirchheiner J. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J Anal Toxicol. 2008;32(2):178-182.
26. Madadi P, Ross CJD, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009;85(1):31-35.
27. Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician. 2007;53(1):33-35.
28. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827-2831.
29. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. Paediatr Anaesth. 2007;17(7):684-687.
30. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257-265.
31. de Wildt SN, Koren G. Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected]. Paediatr Anaesth. 2008 Mar;18(3):273-276. Erratum in: Paediatr Anaesth. 2008;18(5):454.
32. De Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2003;23(4):420-421.
33. Dalén P, Frengell C, Dahl ML, Sjöqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997;19(5):543-544.
34. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol. 1995;15(3):211-216.
35. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
36. Arranz MJ, De Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12(8):707-747.
37. Kirchheiner J, Keulen JTHA, Bauer S, Roots I, Brockmöller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol. 2008;28(1):78-83.
38. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Altieri LP, Perel JM. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull. 1995;31(2):327-332.
39. Meyer JW, Woggon B, Baumann P, Meyer UA. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol. 1990;39(6):613-614.
40. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol. 1992;42(3):347-348.
41. de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 2008;13(2):133-135.
42. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(2):242-251.
43. Kawanishi C, Lundgren S, Ågren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: Ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004;59(11):803-807.
44. Gorny M, Röhm S, Läer S, Morali N, Niehues T. Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism. Eur J Clin Pharmacol. 2010;66(1):107-108.
45. Breil F, Verstuyft C, Orostegui L, et al. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. Int J Neuropsychopharmacol. 2008;11(5):727-728.
46. Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet. 2002;12(1):55-58.
47. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol. 2006;26(2):128-134.
48. Kawanishi C, Shimoda Y, Fujimaki J, et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci. 1998;160(1):102-104.
49. Kato D, Kawanishi C, Kishida I, et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol. 2007;63(11):991-996.
50. Kato D, Kawanishi C, Kishida I, et al. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. Psychiatry Clin Neurosci. 2005;59(4):504-507.
51. Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother. 2008;9(5):787-794.
52. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
53. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 2006;29(7):587-598.
54. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46(6):687-700.
55. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429-436.
56. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci. 1987;499:203-215.
57. Topic E, Stefanovic M, Ivanisevic AM, Blazinic F, Culav J, Skocilic Z. CYP2D6 genotyping in patients on psychoactive drug therapy. Clin Chem Lab Med. 2000;38(9):921-927.
58. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15-27.
59. Vandel P, Bonin B, Vandel S, Sechter D, Bizouard P. CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects. Med Hypotheses. 1996;47(6):439-442.
60. 3H]GBR-12935 binding proteins. Arch Biochem Biophys. 1990;276(2):424-432.
61. Crescenti A, Mas S, Gassó P, Parellada E, Bernardo M, Lafuente A. CYP2D6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol. 2008;35(7):807-811.
62. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284-295.
63. Pope Jr HG, Keck Jr PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143(10):1227-1233.
64. Kawanishi C, Furuno T, Onishi H, et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet. 2000;10(3):145-147.
65. Kawanishi C, Hanihara T, Maruyama Y, et al. Neuroleptic malignant syndrome and hydroxylase gene mutations: No association with CYP2D6A or CYP2D6B. Psychiatr Genet. 1997;7(3):127-129.
66. Iwahashi K, Yoshihara E, Nakamura K, et al. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. Neuropsychobiology. 1999;39(1):33-37.
67. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65(1):57-61.
68. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002;41(7):453-470.
69. Bertilsson L, Dahl ML, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993;341(8836):63.
70. Cheok MH, Pottier N, Kager L, Evans WE. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):39-51.
71. Pottier N, Cheok M, Kager L. Antileukemic drug effects in childhood acute lymphoblastic leukemia. Expert Rev Clin Pharmacol. 2008;1(3):401-413.
72. Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr Opin Pediatr. 2007;19(1):15-22.
73. Ansari M, Krajinovic M. Pharmacogenomics of acute leukemia. Pharmacogenomics. 2007;8(7):817-834.
74. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: A model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6(2):117-129.
75. Brenner TL, Pui CH, Evans WE. Pharmacogenomics of childhood acute lymphoblastic leukemia. Curr Opin Mol Ther. 2001;3(6):567-578.
76. Rogers AJ, Tantisira KG, Fuhlbrigge AL, et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics. 2009;10(8):1231-1242.
77. Qing LD, Tantisira KG. Pharmacogenetics of asthma therapy. Curr Pharm Des. 2009;15(32):3742-3753.
78. Koster ES, Raaijmakers JA, Koppelman GH, et al. Pharmacogenetics of anti-inflammatory treatment in children with asthma: Rationale and design of the PACMAN cohort. Pharmacogenomics. 2009;10(8):1351-1361.
79. Warrier MR, Hershey GK. Asthma genetics: personalizing medicine. J Asthma. 2008;45(4):257-264.
80. Szalai C, Ungvári I, Pelyhe L, Tölgyesi G, Falus A. Asthma from a pharmacogenomic point of view. Br J Pharmacol. 2008;153(8):1602-1614.
81. Weiss ST, Litonjua AA, Lange C, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. 2006;6(5):311-326.
82. Wechsler ME. Managing asthma in the 21st century: the role of pharmacogenetics. Pediatr Ann. 2006;35(9):660-669.
83. Drazen JM, Yandava CN, Dubé L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22(2):168-170.
84. Holmes OW. Currents and Counter-Currents in Medical Science: Medical Essays. 1842-1882. Boston, MA: Houghton-Mifflin; 1891.
85. Oldenkamp C, Wall CA, Mrazek DA. An analysis of the clinical usefulness of psychiatric pharmacogenomic testing in children and adolescents. Poster presented at: the 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 27-November 1, 2009; Honolulu, HI.